Stand out for this role — generate a tailored resume and cover letter in about a minute.
Replimune is seeking an Analyst II, Analytical Development to perform routine analytical testing supporting AD, PD, Research and QC projects. The role is based at Milton Park with a 5-day on-site expectation and requires precise execution of assays.
You will conduct PCR, ELISA, chromatography and cell-based assays, contribute to method development, maintain reagents and SOPs, and ensure GMP compliance while training colleagues.
Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because
patient’s lives depend on it.
People are at the center of everything we do, and when it comes to our employees,
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, a strong and evolving culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to impact on the lives of patients, caregivers and themselves.
The Analyst II, Analytical Development (AD) is primarily responsible for performing routine analytical testing to support AD, Process Development (PD), Research and Quality Control (QC) projects. The Analyst II, AD, also provides support for AD characterization and method development projects. The Analyst II, AD, is also responsible for supporting the day-to-day operation of the Analytical Development (AD) laboratories.
This position is based in our Milton Park location and typically has a 5-day on-site expectation.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.